Public health value of fixed‐dose combinations in hypertension

References

• Corren J. Evaluation and treatment of asthma: An overview. Am J Manag Care 2005; 11((14 Suppl))S408–S415
   Web of Science ®Google Scholar
• Leichter S. B., Thomas S. Combination medications in diabetes care: An opportunity that merits more attention. Clin Diabetes 2003; 21: 175–178
   Google Scholar
• Lewington S., Clarke R., Qizilbash N., Peto R., Collins R. Age‐specific relevance of usual blood pressure to vascular mortality: A meta‐analysis of individual data for one million adults in 61 prospective studies. Lancet 2002; 360: 1903–1913
   PubMed Web of Science ®Google Scholar
• Wolf‐Maier K., Cooper R. S., Kramer H., Banegas J. R., Giampaoli S., Joffres M. R., et al. Hypertension treatment and control in five European countries, Canada, and the United States. Hypertension 2004; 43: 10–17
   PubMed Web of Science ®Google Scholar
• Kearney P. M., Whelton M., Reynolds K., Muntner P., Whelton P. K., He J. Global burden of hypertension: Analysis of worldwide data. Lancet 2005; 365: 217–223
   PubMed Web of Science ®Google Scholar
• Wolf‐Maier K., Cooper R. S., Banegas J. R., Giampaoli S., Hense H‐W., Joffres M., et al. Hypertension prevalence and blood pressure levels in 6 European countries, Canada, and the United States. JAMA 2003; 289: 2363–2369
   PubMed Web of Science ®Google Scholar
• Ezzati M., Lopez A. D., Rodgers A., Vander Hoom S., Murray C. J. L., the Comparative Risk Assessment Collaborating Group. Selected major risk factors and global and regional burden of disease. Lancet 2002; 360: 1347–1360
   PubMed Web of Science ®Google Scholar
• World Health Organization. The World Health Report 2002 – Reducing risks, promoting healthy life. 83, Chapter 4
   Google Scholar
• Mullins C. D., Sikirica M., Seneviratne V., Ahn J., Akras K. S. Comparisons of hypertension‐related costs from multinational clinical studies. Pharmacoeconomics 2004; 22: 1001–1014
   PubMed Web of Science ®Google Scholar
• Chockalingam A., Campbell N. R., Fodor J. G. Worldwide epidemic of hypertension. Can J Cardiol 2006; 22: 553–555
   PubMed Web of Science ®Google Scholar
• Neal B., MacMahon S., Chapman N., Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of ACE inhibitors, calcium antagonists, and other blood‐pressure‐lowering drugs: Results of prospectively designed overviews of randomised trials. Blood Pressure Lowering Treatment Trialists' Collaboration. Lancet 2000; 356: 1955–1964
   PubMed Web of Science ®Google Scholar
• Klungel O. H., Kaplan R. C., Heckbert S. R., Smith N. L., Lemaitre R. N., Longstreth W. T., Jr., et al. Control of BP and risk of stroke among pharmacologically treated hypertensive patients. Stroke 2000; 31: 420–424
   PubMed Web of Science ®Google Scholar
• Hansson L., Zanchetti A., Carruthers S. G., Dahlöf B., Elmfeldt D., Julius S., et al. Effects of intensive blood‐pressure lowering and low‐dose aspirin in patients with hypertension: Principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 1998; 351: 1755–1762
   PubMed Web of Science ®Google Scholar
• ESH–ESC Guidelines Committee. 2003 European Society of Hypertension‐European Society of Cardiology guidelines for the management of arterial hypertension (ESH 2003). J Hypertens 2003; 21: 1011–1053
   PubMed Web of Science ®Google Scholar
• Chobanian A. V., Bakris G. L., Black H. R., Cushman W. C., Green L. A., Izzo J. I., Jr., et al. Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. National Heart, Lung, and Blood Institute; National High Blood Pressure Education Program Coordinating Committee. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. JAMA 2003; 289: 2560–2572
   PubMed Web of Science ®Google Scholar
• Jamerson K. A., Nwose O., Jean‐Louis L., Schofield L., Purkayastha D., Baron M. Initial angiotensin‐converting enzyme inhibitor/calcium channel blocker combination therapy achieves superior blood pressure control compared with calcium channel blocker monotherapy in patients with stage 2 hypertension. Am J Hypertens 2004; 17: 495–501
   PubMed Web of Science ®Google Scholar
• Cushman W. C., Ford C. E., Cutler J. A., Margolis K. L., Davis B. R., Grimm R. H., et al. Success and predictors of blood pressure control in diverse North American settings: The antihypertensive and lipid‐lowering treatment to prevent heart attack trial (ALLHAT). J Clin Hypertens (Greenwich) 2002; 4: 393–404
   PubMedGoogle Scholar
• Julius S., Kjeldsen S. E., Brunner H., Hansson L., Platt F., Ekman S., et al. VALUE trial: Long‐term blood pressure trends in 13,449 patients with hypertension and high cardiovascular risk. Am J Hypertens 2003; 16: 544–548
   PubMed Web of Science ®Google Scholar
• Walley T., Duggan A. K., Haycox A. R., Niziol C. J. Treatment for newly diagnosed hypertension: Patterns of prescribing and antihypertensive effectiveness in the UK. J Royal Soc Med 2003; 96: 525–531
   PubMed Web of Science ®Google Scholar
• Lloyd A., Schmieder C., Marchant N. Financial and health costs of uncontrolled blood pressure in the United Kingdom. Pharmacoeconomics 2003; 21(Suppl 1)33–41
   PubMed Web of Science ®Google Scholar
• Flack J. M., Casciano R., Casciano J., Doyle J., Arikian S., Tang S., et al. Cardiovascular disease costs associated with uncontrolled hypertension. Manag Care Interface 2002; 15: 28–36
   PubMedGoogle Scholar
• Degli Esposti L., Valpiani G. Pharmacoeconomic burden of undertreating hypertension. Pharmacoeconomics 2004; 22: 907–928
   PubMed Web of Science ®Google Scholar
• Black H. R., Elliott W. J., Grandits G., Grambsch P., Lucente T., White W. B., et al. Principal results of the Controlled Onset Verapamil Investigation of Cardiovascular End Points (CONVINCE) trial. JAMA 2003; 289: 2073–2082
   PubMed Web of Science ®Google Scholar
• Burnier M. Medication adherence and persistence as the cornerstone of effective antihypertensive therapy. Am J Hypertens 2006; 19: 1190–1196
   PubMed Web of Science ®Google Scholar
• World Health Organization (WHO). Adherence to long term therapies: Evidence for action. 2003, WHO
   Google Scholar
• International Society for Pharmacoeconomics and Outcomes Research (ISPOR), Pharmacoeconomic guidelines around the word. http://www.ispor.org/PEguidelines/index.asp (accessed on 25 August 2006).
   Google Scholar
• Berger M. L., Bingefors K., Hedblom E. C., , editors, et al. Health care cost, quality and outcomes: ISPOR book of terms. 2003, ISPOR
   Google Scholar
• Sturkenboom M. C. J. M., Picelli G., Dieleman J. P., Mozaffari E., Pompen M., van der Lei J. Patient adherence and persistence with antihypertensive therapy: One‐versus two‐pill combinations. J Hypertens 2005; 23(Suppl 2)S326
   Google Scholar
• DiMatteo M. R., Giordani P. J., Lepper H. S., Croghan T. W. Patient adherence and medical treatment outcomes: A meta‐analysis. Med Care 2002; 40: 794–811
   PubMed Web of Science ®Google Scholar
• Dezii C. M. Medication noncompliance: What is the problem?. Manag Care 2000; 9((9 Suppl))S7–S12
   PubMedGoogle Scholar
• Taylor A. A., Shoheiber O. Adherence to antihypertensive therapy with fixed‐dose amlodipine besylate/benazepril HCl versus comparable component‐based therapy. Congest Heart Fail 2003; 9: 324–332
   PubMedGoogle Scholar
• Davis T. C., Wolf M. S. Health literacy: Implications for family medicine. Fam Med 2004; 36: 595–598
   PubMed Web of Science ®Google Scholar
• Caro J. J., Speckman J. L., Salas M., Raggio G., Jackson J. D. Effect of initial drug choice on persistence with antihypertensive therapy: The importance of actual practice data. CMAJ 1999; 160: 41–46
   PubMed Web of Science ®Google Scholar
• Hughes D., McGuire A. The direct costs to the NHS of discontinuing and switching prescriptions for hypertension. J Hum Hypertens 1998; 12: 533–537
   PubMed Web of Science ®Google Scholar
• Osterberg L., Blaschke T. Adherence to medication. N Engl J Med 2005; 353: 487–497
   PubMed Web of Science ®Google Scholar
• Halpern M. T., Vincze G., Stewart W. F., Khan Z. M. Persistence with hypertension therapy and long‐term cardiovascular outcomes. J Hypertens 2006; 24(Suppl 4)S182–S183, (P11.86)
   Google Scholar
• Breekveldt‐Postma N. S., Siiskonen S. J., Penning‐Van Beest F. J. A., et al. Non‐persistent use of antihypertensive drugs leads to increased risk of hospitalizations for acute myocardial infarction or stroke. Value Health 2006; 9(Suppl)A339
   Google Scholar
• Granger B. B., Swedberg K., Ekman I., Granger C. B., Olofsson B., McMurray J. J., et al. Adherence to candesartan and placebo and outcomes in chronic heart failure in the CHARM programme: Double‐blind, randomised, controlled trial. Lancet 2005; 366: 2005–2011
   PubMed Web of Science ®Google Scholar
• Cleemput I., Kesteloot K., DeGeest S. A review of the literature on the economics of non‐complicance. Room for methodological improvement. Health Policy 2002; 59: 65–94
   PubMed Web of Science ®Google Scholar
• McCombs J. S., Nichol M. B., Newman C. M., Sclar D. A. The costs of interrupting antihypertensive drug therapy in a Medicaid population. Med Care 1994; 32: 214–226
   PubMed Web of Science ®Google Scholar
• Sokol M. C., McGuigan K. A., Verbrugge R. R., Epstein R. S. Impact of medication adherence on hospitalization risk and healthcare cost. Med Care 2005; 43: 521–530
   PubMed Web of Science ®Google Scholar
• Levy G., Zamacona M. K., Jusko W. J. Developing compliance instructions for drug labeling. Clin Pharmacol Ther 2000; 68: 586–591
   PubMed Web of Science ®Google Scholar
• Rizzo J. A., Abbott T. A., 3rd., Pashko S. Labour productivity effects of prescribed medicines for chronically ill workers. Health Econ 1996; 5: 249–265
   PubMed Web of Science ®Google Scholar
• Jamerson K. A., Bakris G. L., Wun C. C., Dahlöf B., Lefkowitz M., Manfreda S., et al. Rationale and design of the avoiding cardiovascular events through combination therapy in patients living with systolic hypertension (ACCOMPLISH) trial: The first randomized controlled trial to compare the clinical outcome effects of first‐line combination therapies in hypertension. Am J Hypertens 2004; 17: 793–801
   PubMed Web of Science ®Google Scholar
• Jamerson K., Bakris G. L., Dahlöf B., Pitt B., Velazquez E., Gupte J., et al. ACCOMPLISH Investigators. Exceptional early blood pressure control rates: The ACCOMPLISH trial. Blood Press 2007; 16: 80–86
   PubMed Web of Science ®Google Scholar
• Ruilope L. M., Malacco E., Khder Y., Kandra A., Bönner G., Heintz D. Efficacy and tolerability of combination therapy with valsartan plus hydrochlorothiazide compared with amlodipine monotherapy in hypertensive patients with other cardiovascular risk factors: The VAST study. Clin Ther 2005; 27: 578–587
   PubMed Web of Science ®Google Scholar
• Andreadis E. A., Tsourous G. I., Marakomichelakis G. E., Katsanou P. M., Fotia M. E., Vassilopoulos C. V., Diamantopoulos E. J. High‐dose monotherapy vs low‐dose combination therapy of calcium channel blockers and angiotensin receptor blockers in mild to moderate hypertension. J Hum Hypertens 2005; 19: 491–496
   PubMed Web of Science ®Google Scholar
• Neutel J., Smith D. H. Evaluation of angiotensin II receptor blockers for 24‐hour blood pressure control: Meta‐analysis of a clinical database. J Clin Hypertens (Greenwich) 2003; 5: 58–63
   PubMedGoogle Scholar
• Wanovich R., Kerrish P., Gerbino, Shoheiber O. Compliance patterns of patients treated with two separate antihypertensive agents versus fixed‐dose combination therapy. Am J Hypertens 2004; 17: 223A
   PubMed Web of Science ®Google Scholar
• Dickson M., Plauschinat C. A. Antihypertensive therapy compliance and total cost of care in a Medicaid population: Fixed‐dose combination vs free‐combination treatment. Am J Health Syst Pharm 2005; 62: P71E
   Google Scholar
• Hilleman D. E., Reyes A. P., Wurdeman R. L., Faulkner M. Efficacy and safety of a therapeutic interchange from high‐dose calcium channel blockers to a fixed‐dose comfobination of amlodipine/benazepril in patients with moderate‐to‐severe hypertension. J Hum Hypertens 2001; 15: 559–565
   PubMed Web of Science ®Google Scholar
• Kountz D. S. Cost containment for treating hypertension in African Americans: Impact of a combined ACE inhibitor‐calcium channel blocker. J Natl Med Assoc 1997; 89: 457–460
   PubMed Web of Science ®Google Scholar
• Dezii C. M. A retrospective study of persistence with single‐pill combination therapy vs. concurrent two‐pill therapy in patients with hypertension. Manag Care 2000b; 9(Suppl)S2–S6
   PubMedGoogle Scholar
• Jackson K., Brixner D., Oderda G., et al. Persistence of fixed versus free combination therapy with valsartan and HCTZ for patients with hypertension. Value Health 2006; 9(Suppl)A363
   Google Scholar
• Drummond M., Jonsson B. Moving beyond the drug budget silo mentality in Europe. Value Health 2003; 6(Suppl 1)S74–S77
   Google Scholar
• Wertheimer A., Santella T. M., Finestone A. J., Levy R. Clinical and economic advantages of modern dosage forms: Improving medication adherence. 2006, Center for Pharmaceutical Health Services Research
   Google Scholar
• Kalo Z., Muszbek N., Bodrogi J., Bidlo J. Does therapeutic reference pricing always result in cost‐containment? The Hungarian evidence. Health Policy 2006; 89: 401–412
   Google Scholar
• Lopez‐Casasnovas G., Puig‐Junoy J. Review of the literature on reference pricing. Health Policy 2000; 54: 87–123
   PubMed Web of Science ®Google Scholar
• Atella V., Peracchi F., Depalo D., Rossetti C. Drug compliance, co‐payment and health outcomes: Evidence from a panel of Italian patients. Health Economics 2006; 15: 875–892
   PubMed Web of Science ®Google Scholar
• Andersson K., Petzold M. G., Sonesson C., Lonnroth K., Caristen A. Do policy changes in the pharmaceutical reimbursement schedule affect drug expenditures? Interrupted time series analysis of cost, volume and cost per volume trends in Sweden 1986–2002. Health Policy 2006; 79: 231–243
   PubMed Web of Science ®Google Scholar
• Kanavos P., Reinhardt U. Reference pricing for drugs: Is it compatible with US health care?. Health Affairs (Millwood) 2003; 22: 16–30
   PubMed Web of Science ®Google Scholar
• Koopmanschap M. A., Rutten F. F. H. The drug budget silo mentality: The Dutch case. Value Health 2003; 6(Suppl 1)S46–S51
   Google Scholar
• Puig‐Junoy J. Incentives and pharmaceutical reimbursement reforms in Spain. Health Policy 2004; 67: 149–165
   PubMed Web of Science ®Google Scholar
• World Health Organization Collaborating Centre for Drug Statistics Methodology (WHO), About the ATC/DDD system: http://www.whocc.no/atcddd/6 (Last accessed 25 August 2006).
   Google Scholar